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Abstract 
Superparamagnetic iron oxide nanoparticles (SPIONs) and core-shell type nanoparticles, 
consisting of SPIONs coated with mesoporous silica and/or lipid, were synthesized and tested 
for their potential theranostic applications in drug delivery, magnetic hyperthermia and as a 
contrast agent. Transmission Electron Microscopy (TEM) confirmed the size of bare and 
coated SPIONs was in the range of 5-20 nm and 100-200 nm respectively. The 
superparamagnetic nature of all the prepared nanomaterials as indicated by Vibrating Sample 
Magnetometry (VSM) and their heating properties under an AC field confirm their potential 
for hyperthermia applications. Scanning Column Magnetometry (SCM) data showed that 
extrusion of bare-SPION (b-SPION) dispersions through a 100 nm polycarbonate membrane 
significantly improved the dispersion stability of the sample. No sedimentation was apparent 
after 18 hours compared to a pre-extrusion estimate of 43% settled at the bottom of the tube 
over the same time. Lipid coating also enhanced dispersion stability. Transversal relaxation 
time (T2) measurements for the nanoparticles, using a bench-top relaxometer, displayed a 
significantly lower value of 46 ms, with a narrow relaxation time distribution, for lipid silica 
coated SPIONs (Lip-SiSPIONs) as compared to that of 1316 ms for the b-SPIONs. Entrapment 
efficiency of the anticancer drug, Doxorubicin (DOX) for Lip-SPIONs was observed to be 35% 
which increased to 58% for Lip-SiSPIONs. Moreover, initial in-vitro cytotoxicity studies 
against human breast adenocarcinoma, MCF-7 cells showed that % cell viability increased 
from 57% for bSPIONs to 82% for Lip-SPIONs and to 87% for Lip-SiSPIONs. This suggests 
that silica and lipid coatings improve the biocompatibility of bSPIONs significantly and 
enhance the suitability of these particles as drug carriers. Hence, the magnetic nanomaterials 
prepared in this work have potential theranostic properties as a drug carrier for hyperthermia 
cancer therapy and also offer enhancement of contrast agent efficacy and a route to a significant 
increase in dispersion stability. 
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Introduction 
Cancer is one of the most devastating diseases in the world, causing millions of fatalities every 
year. Over the past two decades, the mortality rate has significantly reduced due to considerable 
progress in diagnosis and treatment of the disease (Siegel et al., 2018). However, all the current 
treatments such as surgery, chemotherapy and radiation are unpleasant, pose a risk of 
recurrence of disease and lack specificity, causing toxicity and undesirable side effects. To 
tackle the limitations of conventional anti-cancer treatments, a significant and increasing 
proportion of recent research has been focussed on understanding the biological interactions of 
existing drugs on a cellular level and developing new drugs (Fahs et al., 2015, Palmer et al., 
2018, Fahs et al., 2014) . Moreover, new strategies offering a targeted approach to deliver the 
drug to a cancer site, such as immunotherapy (Milling et al., 2017, Riley et al., 2019), gene 
therapy (Amreddy et al., 2018), laser treatment (Doughty et al., 2019) and hyperthermia 
(Sharma et al., 2018, Blanco-Andujar et al., 2018, Phung et al., 2019), have been explored.  
 
Nanotechnlogy is emerging as a powerful tool in providing ways to manufacture materials to 
treat diseases including cancer. Nanoparticles in the size range between 1-100 nm have proven 
to be an effective therapeutic carrier system for drug delivery applications (Wakaskar, 2018, 
Wang et al., 2018, Aghebati-Maleki et al., 2020). Hydrophilic and/or hydrophobic drugs can 
be encapsulated in the nanoparticles, thus reducing the toxicity of the drug and enhancing its 
solubility. Moreover, their small size and large surface to volume ratio improve their blood 
circulation and thus enhance their intracellular uptake (Donahue et al., 2019). As lipids are an 
integral part of a membrane, liposomes present an ideal biocompatible system and hence these 
are one of the oldest nanoparticles to be used in medicine (Alavi and Hamidi, 2019, Lee and 
Im, 2019, Patil-Sen et al., 2004). However, limitations associated with liposomes are in their 
pharmaceutical development i.e. reproducibility and reliability, long term structural stability 
and chemical instability or denaturation of the encapsulated compound in the manufacturing 
process (Sercombe et al., 2015). Several other types of nanoparticles (NPs) have been 
extensively researched for therapeutic applications which include micelles, dendrimers, 
polymeric, metallic, silica and cell membrane coated nanoparticles (Narain et al., 2017, Patil-
Sen Y., 2019, Khan et al., 2019, Janko et al., 2019, Yang et al., 2019).  
 
Out of the mentioned NPs, superparamagnetic iron oxide nanoparticles (SPIONs) have shown 
great potential in theranostic applications, such as their use as a contrast agent in magnetic 
resonance imaging (MRI), in separation of biomolecules and in targeted drug delivery 
(Cardoso et al., 2018, Patil-Sen and Chhabria, 2018, Janko et al., 2019). As a consequence of 
their superparamagnetic properties, SPIONs are increasingly explored in hyperthermia cancer 
therapy (Hergt et al., 2006, Verma et al., 2014, Janko et al., 2019). SPIONs exhibit no net 
magnetic moment in zero applied field but respond readily (relatively high permeability) in the 
presence of an external magnetic field and can thereby be directed specifically to the cancer 
cells. The therapeutic agent can then be released to the target cells by inducing local 
hyperthermia with an applied AC field which is advantageous for localized therapy.  
 
Typically, MRI contrast agents are either paramagnetic lanthanide complexes, mostly 
containing gadolinium ions and which provide positive contrast in T1-weighted images (spin-
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lattice relaxation time), or iron oxide-based nanoparticles, such as SPIONs, which provide 
negative contrast in T2-weighted images (spin-spin relaxation time) (Estelrich et al., 2015, 
Pellico et al., 2019). The limitations associated with T1 contrast agents are poor detection 
sensitivity, short blood circulation and toxicity concerns (Estelrich et al., 2015) whereas the 
major drawback of T2 agents is in its contrast mechanism, which produces a signal-decreasing 
effect (Pellico et al., 2019). To overcome these limitations, there is a need to enhance the 
properties of current contrast agents or search for a dual or all-in-one contrast agent. Unlike the 
gadolinium-based ions, which only act as T1 contrasting agents, SPIONs can be tuned to 
function either as T1 or T2 by controlling the size of the NPs. SPIONs with particle size <10 
nm, act as T1 agents whereas those above act as T2 (Estelrich et al., 2015). Thus, controlling 
the size of SPIONs is a critical challenge for their application in MR imaging.  
 
Another major issue associated with SPIONs is their propensity to aggregate (Hufschmid et 
al., 2019). Agglomeration of nanoparticles further reduces their stability in dispersion which 
may have a negative effect on their in-vivo applications. One of the strategies that is researched 
for controlling their agglomeration is to coat the surface of SPIONs with materials such as 
polymers (Zhu et al., 2018) and lipids (Luchini and Vitiello, 2019). The coating may fully 
cover one individual particle or relatively small multi-cores rather than larger agglomerates of 
variable size and shape. Thus, such surface modification not only enhances the stability of the 
suspension but also aids in controlling the size of the NPs, both of which are important 
parameters for in-vivo applications of SPIONs in hyperthermia drug delivery and MRI 
applications (Patil et al., 2016, Hola et al., 2015).   
 
Lipid coated SPIONs, also called magnetoliposomes, have gathered a lot of attention over the 
years and have been explored for their potential applications in biomedicine in a number of 
reviews (Soenen et al., 2009, Reimhult, 2015, Heidarli et al., 2017). These hybrid systems 
provide synergistic properties as they combine the unique features of both i.e. properties of the 
magnetic NPs and biocompatibility of an outer lipid bilayer. Although these systems show 
great promise for hyperthermia cancer therapy, therapeutic efficacy of these systems, due to 
poor encapsulation efficiency of the drug, is still a challenge.  In addition, there is a tendency 
in these articles to focus solely on either material characterisation or cellular efficacy as 
opposed to investigating both sets of properties as in the study reported here.  Of those that 
consider both, Pradhan et al. reported that thermosensitive folate-targeted DOX-containing 
magnetic liposomes with multifunctional properties showed enhanced in-vitro cytotoxicity 
against human epidermoid carcinoma and human cervical carcinoma in comparison with their 
non-magnetic folate-targeted liposome counterpart (Pradhan et al., 2010). In another study, 
Kulshrestha and co-workers prepared paclitaxel loaded thermosensitive magnetoliposomes 
which were found to show a 46-fold higher drug release under an AC magnetic field of intensity 
10 kA/m and a fixed frequency of 423 kHz (Kulshrestha et al., 2012). They further reported 
that the in-vitro cellular cytotoxicity of the drug loaded magnetoliposomes against human 
cervical cells was much higher with magnetic hyperthermia than either chemotherapy or 
hyperthermia alone. Methotrexate modified thermosensitive magnetoliposomes were 
developed by Guo et al. for precise cervical cancer therapy (Guo et al., 2018). Light and 
magnetic hyperthermia triggered release of DOX increased its uptake into the tumour cells and 
enhanced its cytotoxicity to the cancerous cells as indicated by both in-vitro and in-vivo results. 
Szuplewska and researchers developed nanocarriers consisting of hydrophobic iron oxide NPs 
coated with the lipid bilayer for magnetic field-assisted selective delivery of DOX to breast 
cancer cells (Szuplewska et al., 2019). Askari et al. reported magnetoliposomes made of 
magnetic NPs and PolyEthylene Glycol-ated (PEGylated) liposomes for in-vitro DOX delivery 
against human breast cancer cells (Askari et al., 2020). They compared their results with 
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liposome-only PEGylated DOX and found the inclusion of a magnetic core enhanced drug 
encapsulation efficiency from around 25% to 37%. 
 
Lipid coatings may also be applied to dual core-shell systems consisting of a magnetic NP core 
and non-magnetic shell and are defined here as nanocomposites or composite-
magnetoliposomes. These systems offer the advantage of both drug encapsulation in the shell 
combined with the biocompatibility of the outer lipid layer when compared to just core-shell 
composites. Reports on these dual-coated systems in terms of their theranostic applications are 
limited. Pradhan et al. developed a pH sensitive and thermosensitive system consisting of lipid-
coated mesoporous silica-shell magnetic core nanoassemblies as a delivery system for 
thermochemotherapy of dual drugs i.e. DOX and paclitaxel (Pradhan et al., 2014). They 
observed that the intracellular uptake and cellular toxicity, on human cervical cancer, breast 
cancer and human hepatocellular carcinoma, for the dual drug loaded system was higher than 
that for the single drug system which was further enhanced by magnetic hyperthermia. 
Sharifabad and authors produced lipid and/or mesoporous silica coated SPIONs for their 
potential application in delivery of Mitomycin C (Sharifabad et al., 2015). They showed single 
and dual coatings resulted in very different drug loading and release profiles and thereby a 
possible route for tuning rate and load delivery to match that of clinical need. In another study, 
the researchers fabricated a system of soy-phosphatidyl choline/cholesterol lipid and/or 
mesoporous silica coated SPIONs, but in this case using DOX as the anticancer drug. They 
tested the cellular toxicity of these novel particles in-vitro against breast cancer and glioma 
cells and found that magnetic hyperthermia lowered the survival rate of these cells by around 
20% compared to that of DOX alone (Sharifabad et al., 2016). 
 
To the best of our knowledge there are no reports on contrast agent investigations using a three-
component composite-magnetolipsome. Herein, we report on the fabrication of such a system, 
consisting of a SPION-silica core-shell coated with an outer lipid layer, and on its potential and 
novel application in enhancing the T2 relaxation time parameter required for negative contrast 
in MRI imaging. In addition, we report on the increased stability provided by the dual coating 
using a fully quantitative technique (scanning column magnetometer) that takes advantage of 
the magnetic properties in order to provide complete settling profiles of particle concentration 
over the height of a column of dispersion.  Enhancements of in-vitro drug-loading efficiency 
and release due to the silica coating and in biocompatibility due to the lipid layer are also 
studied. These are important findings for MRI and hyperthermia-mediated targeted drug 
delivery and supports their potential use as theranostic systems for cancer therapy. 
  
Materials and Methods 
Iron (II) chloride tetrahydrate (FeCl2, 4H2O), Iron (III) chloride hexahydrate (FeCl3, 6H2O), 
cetyl trimethyl ammonium bromide (CTAB), tetraethyl orthosilicate (TEOS), dipalmitoyl 
phosphatidylcholine (DPPC), cholesterol (Ch), phosphate buffered saline (PBS), methanol, 
chloroform, ammonium hydroxide (NH4OH, 28-30 wt% ammonia in water), sulphuric acid 
(H2SO4, 0.1M in water) were purchased from Sigma-Aldrich, UK. Doxorubicin hydrochloride 
(DOX) was purchased from Cayman Chemical. PrestoBlue cell viability reagent was obtained 
from Invitrogen. Eagle's Minimum Essential Medium (EMEM), Fetal Bovine Serum (FBS), 
L-glutamine, Non-Essential Amino Acids (NEAA), and Sodium Pyruvate were purchased 
from Lonza, UK. All the chemicals were analytical grade and were used as purchased. Non-
cancerous human foetal glial cell line, SVG p12 and human breast cancer commercial cell line, 
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MCF-7 (ATCC) were kindly provided by UCLan’s Biomedical Research Facilities. Milli-Q 
water (resistivity = 18 MΩ∙cm) was used in all experiments. 
 
Synthesis of SPIONs 
Bare SPIONs (bSPIONs) were prepared by the co-precipitation method using ferrous and ferric 
chloride, in 1:2 mole ratio in alkaline media and under an inert atmosphere, as previously 
reported (Majid et al., 2017). Briefly, 8.46 g (0.04 mol) FeCl2, 4H2O and 22.95 g (0.08 mol) 
FeCl3, 6H2O were dissolved in 500 ml deionized water previously degassed with nitrogen. The 
mixture was kept at 80°C under nitrogen atmosphere while 50 mL of aqueous NH4OH (28-30 
wt%) was added drop wise to the mixture over 30 min under vigorous stirring. The reaction 
was allowed to proceed for a further 1 hour under nitrogen atmosphere. The black reaction 
product, Fe3O4, was washed to neutral pH several times using deionized water and magnetic 
separation. 
 
Synthesis of silica coated SPIONs 
Mesoporous silica coated SPIONs (SiSPIONs) were prepared using a surfactant templating 
approach via a hydrolysis and condensation mechanism. 480 mg of bSPIONs were dispersed 
in 200 ml of methanol/water (4/1, V/V) solution. 14 ml of NH4OH (28-30 wt%) solution was 
added to the mixture and stirred for 5 minutes. 10 g CTAB was then added to the solution and 
the suspension was homogenized by an ultrasonic bath for 15 minutes. To the reaction mixture, 
6 mL TEOS was added drop-wise under vigorous stirring for 16 hours. The resultant black 
product was isolated from the reaction mixture and washed several times with acidic methanol 
solution (2/49/49 v% of 0.1M H2SO4/methanol/deionized water) in an ultrasonic bath to 
remove the surfactant from the mesopores, followed by subsequent washing with deionized 
water. 
 
Preparation of lipid coated bSPIONs/ SiSPIONs (Lip-SPIONs/Lip-SiSPIONs) 
Lipid coated nanoparticles were prepared by the thin film hydration method. The lipid mixture 
of DPPC/Ch, in 7:3 (w/w ratio) was prepared by dissolving 42 mg of DPPC and 18 mg of Ch 
in 3 ml chloroform/methanol (2:1 v/v) in a round bottomed flask. The organic solvent was 
removed under vacuum by a rotary evaporator, using a water bath at 50 °C for 1 hour. A thin 
film of lipid was formed inside the flask which was further dried under nitrogen gas for 2 hours 
to remove any traces of organic solvent remaining. The lipid film was hydrated by adding 6 ml 
of deionized water, vortexed for 2 minutes, and then mixed using a rotavapor (without vacuum) 
in a water bath at 50 °C for 1 hour and finally kept for annealing at room temperature for 2 
hours.  60 mg of bSPIONs in 6 ml deionized water was added to the lipid mixture to make a 
1:1 Lip-SPION nanocomposite. The lipid-SPIONs nanocomposite was placed in an ice bath 
and ultrasonicated (ULT065 from Ultrawave, Cardiff, UK) for 5 minutes, with a continuous 
pulse at 40 % power. The excess lipid in the suspension was removed using magnetic 
separation. Lipid coated SiSPIONs were prepared following the same procedure. Figure 1 
summarizes the synthesis procedure for preparation of lipid and/or silica coated SPIONs. 
 
DOX loading onto bSPIONs, SiSPIONs, and Lip-SPIONs and Lip-SiSPIONs 
The prepared nanoparticles were dispersed for 15 minutes using a bath sonicator. DOX loaded 
nanoparticles were prepared by mixing a 1:500 (w/w) ratio of DOX: nanoparticle, at 18 °C 
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using end over end rotation for 48 hours. The amount of DOX that was loaded into the 
nanoparticles at different time intervals was determined by using a UV spectrophotometer. To 
quantify the amount of drug loaded into the nanoparticles, the drug loaded nanoparticles were 
centrifuged at 2000 rpm for 1 minute followed by magnetic separation. The absorbance of the 
supernatant was measured at = 484 nm and was compared with a pre-established curve of  
known DOX concentrations in DMSO: water (1:1) to establish the concentration of the drug in 
the supernatant. The calibration curve is shown in Figure A2 of the Appendix section. The 
amount of drug loaded in the nanoparticles was obtained by measuring the difference in 
concentration of DOX between the amount initially added, [T(DOX)], and the amount 
remaining in the supernatant, [S(DOX)], over time. All the measurements were carried out in 
triplicate. Hence, the percentage of drug entrapment efficiency (% EE) was calculated using 
equation 1: 
 
% EE = [୘(ୈ୓ଡ଼)]ି[ୗ(ୈ୓ଡ଼)]
[்(஽ை௑)]
 x 100     (1) 
 
 
Figure 1: Schematic representation of synthesis procedure for the SPION core and core-shell SPIONs. 
 
 
DOX-loaded nanoparticles were washed 3 times with deionized water and stored at 4 °C until 
further use for lipid coating, drug release studies and in-vitro cytotoxicity studies. 
 
Characterisation 
Magnetic measurements were performed at room temperature using an in-house 6 kOe 
Vibrating Sample Magnetometer (VSM). The samples were first dried and ground into a fine 
powder and then packed into plastic tubes of length ~10 mm and internal diameter ~1.9 mm. 
Typically 20-50 mg of magnetic materials were used for the measurements. The saturation 
magnetization values were expressed as (emu/g).   
 
Transmission electron micrographs were obtained from a JEOL JEM2000EX (JEOL, Japan) 
instrument operating at an accelerating voltage of 200 kV. TEM samples were prepared by 
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placing a drop of sample dispersion onto a carbon-coated copper grid using a pipette and drying 
at room temperature before placing into the TEM instrument. The images were collected using 
a digital camera and analysed using Gatan software.  
 
The ability of the nanocomposites to generate heat in the presence of an oscillating magnetic 
field was evaluated by a DM100-Series Nanoheating Instrument (nanoScale Biomagnetics, 
Spain), at field frequency of 406 kHz and flux density of 200 gauss. The vial with dispersion 
containing magnetic nanoparticles at a concentration of 10 mg/ml was placed inside a magnetic 
coil loop which generated an oscillating magnetic field. The temperature was measured using 
a fibre optic sensor probe by dipping it in the dispersion. System embedded software, MaNIaC, 
was used to control the experimental parameters and to collect the generated data. The 
maximum temperature was set at 43°C which is sufficient for classical hyperthermia treatment 
for cancer therapy (Kobayashi, 2011). The efficiency of induced heat of magnetic materials 
was measured as the specific absorption rate (SAR). SAR reflects the heat transformation from 
magnetic energy, as shown in equation 2. 
 
𝑆𝐴𝑅 = ௖
ெmnp
ቀ௱்
௱௧
ቁ      (2) 
 
where c is specific heat capacity of the medium and ௱்
௱௧
 reflects the initial slope of temperature 
change as a function of time during the heat induction and Mmnp is the mass fraction of magnetic 
nanoparticles (Vallejo-Fernandez et al., 2013, Rovers, 2010). The medium of dispersion was 
water in our samples and since the amount of magnetic nanoparticles was negligible compared 
to the amount of water, the value of c can be taken as the specific heat capacity of water = 
4.184 J/g.K (Motoyama et al., 2008). 
 
Stability measurements 
A Scanning Column Magnetometry (SCM) technique was used to examine the effect of lipid 
coating on SPIONs on the dispersion stability of the nanoparticles. The effect of extrusion on 
dispersion stability of bSPIONs was also investigated. For this, the SPIONs were extruded 5 
times through a 100 nm polycarbonate membrane using a lipofast extruder (Avestin Europe 
GmbH, Germany). Full details of the SCM technique can be found elsewhere (Mercer and 
Bissell, 2013), but in summary this includes the nanoparticle dispersion being filled into a 
vertically held glass tube with internal diameter 11 mm to produce a column height of 10 to 12 
cm. This is then placed in the otherwise empty core of a coil that forms part of an oscillatory 
circuit. By effectively scanning the coil over the height of the tube, any magnetic material 
present at that point causes an increase in the coil inductance and a corresponding shift in the 
resonance frequency, ΔF, from its sample-free value of 1 MHz. As this is directly proportional 
to the particle volume concentration, profiles of ΔF as a function of column height correspond 
to a whole concentration profile of the magnetic fluid. By obtaining a series of these profiles 
over time, any change in magnetic particle concentration due to sedimentation, and hence the 
dispersion stability, can be investigated. 
 
T2 measurements 
 
Relaxation times for protons were measured using a Bruker Minispec (mq 60) bench-top 
relaxometer operating at 60 MHz (magnetic flux density: 1.41 T). The transversal relaxation 
times (T2) were determined by the Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence. The 
CPMG is a type of spin echo pulse sequence consisting of a 90° radio frequency (RF) pulse 
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followed by an echo train induced by n successive 180° pulses (refocusing pulses): (90° − τ − 
{180° − 2τ}sn) (de Andrade et al., 2011). T2 relaxation time distributions for all samples were 
computed by applying the CONTIN algorithm (Bruker Software) to the measured data. Data 
were fitted using a biexponential curve to detect multiple components (fast and slow T2) 
contributing to the relaxation. All measurements were carried out at 37°C and repeated at least 
in triplicate. 
 
DOX release efficiency of nanoparticles 
The drug release studies were carried out in PBS. DOX loaded nanoparticles were washed three 
times and then incubated in PBS at 37 °C using end over end rotation for 48 hours. Time 
dependent release profiles were obtained using UV absorbance at = 484 nm and by comparing 
the data with the pre-established curve of known DOX concentrations in PBS. The release of 
DOX from the nanoparticles using magnetic hyperthermia to raise the temperature to, and then 
hold at, 37 °C was also examined and compared with that in the absence of a magnetic field.  
 
In-vitro cytotoxicity studies  
The cytotoxicity of the nanoparticles was investigated against MCF-7 cells. The cells were 
cultured in EMEM supplemented with 10% (v/v) FBS, 1% NEAA and 1% L-glutamine in a 
humidified incubator at 37 °C, 5% CO2. Cells were harvested at the logarithmic growth phase 
and seeded in 96-well plates at a density of 2000 x104 cells in 90 µl EMEM per well. Cells 
were maintained in complete growth medium for 24 h at 37°C in a humidified atmosphere with 
5% CO2. After 24 h, the medium was removed and replaced with 90 μl of media containing 
nanocomposites in different concentrations, i.e. 125, 250 and 500 μg/ml (which correspond to 
0.25, 0.5 and 1µg/ml DOX concentrations respectively). The dose dependent cytotoxicity was 
evaluated by incubating cells for 24, 48 and 72 hours and performing a PrestoBlue assay. These 
concentrations of nanocomposites were chosen based on the initial dose dependent studies 
carried out on nanoparticles and DOX. The nanocomposites were also tested for their 
biocompatibility and cellular toxicity against in-house SVG p12 cells which are non-cancerous 
foetal glial cells. 
 
To perform the assay, 10μl of PrestoBlue reagent was added to each well. The plates were 
covered with aluminium foil and incubated for 30 min. The fluorescence was measured using 
excitation at 535 nm and emission at 612 nm using a Tecan Genius Pro Plate Reader. From 
these results, the % cell viability was calculated using equation 3 
 
% cell viability = ୅ୠୱ୭୰ୠୟ୬ୡୣ ୭୤ ୲୰ୣୟ୲ୣୢ ୱୟ୫୮୪ୣ 
୅ୠୱ୭୰ୠୟ୬ୡୣ ୭୤ ୡ୭୬୲୰୭୪ 
 x 100    (3) 
 
 
Statistical analysis 
 
All results are expressed as the mean of three independent experiments at three different times 
with error bars presenting the standard deviation. For the cytotoxicity study, in each 
experiment, measurements were carried out in six wells. IC50 values were calculated using 
Microsoft Excel. A linear regression trendline was applied to the log-linear plots of cell 
viability as a function of concentration. The software’s Data Analysis tool was employed to 
calculate the 95% CI values. Statistical analysis was also performed using Microsoft Excel, t-
tests, one-tailed, paired: where p < 0.05 was considered statistically significant. 
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Results and Discussion 
VSM results  
 
The magnetization curves for the prepared magnetic nanoparticles obtained from VSM 
measurements are presented in Figure 2. In the bulk these iron oxides are ferrimagnets with 
distinct hysteresis loops and associated remanence and coercivity. For example, magnetite  has 
a saturation magnetization, Ms, of around 92 emu/g and coercive field values, Hc, in the range 
100 to 400 Oe (Ahmadzadeh et al., 2018). However, reduction in size into the range of tens of 
nanometres leads to a change in magnetic behaviour:  at room temperature the energy of 
thermal agitation is now greater than that of the magnetic ordering and the material exhibits a 
paramagnetic-like response, with zero magnetic moment in zero field (Gupta and Gupta, 2005, 
Dunlop, 1973, Goya et al., 2003). On application of an external field the moments readily align 
to give relatively large Ms values compared to conventional paramagnetism and hence the term 
Superparamagnetic. For biomedical applications, such superparamagnetic particles are 
preferred due to this property of no retained magnetization (zero remanence, Mr) once the 
magnetic field is removed. 
 
 
 
Figure 2: Magnetization curves for bSPIONs SiSPIONs, lipid coated bSPIONs and lipid coated SiSPIONs.  
 
As can be seen from the Figure 2, the prepared nanoparticles show small hysteresis with 
coercivity values of order tens of Oe, being indicative of the superparamagnetic nature of the 
synthesized particles (Goya et al., 2003). It should also be noted that increasing dipolar 
interactions between particles results in the emergence of hysteresis in otherwise purely 
superparamagnetic particles (Petracic, 2010). As there is evidence of agglomeration in the 
TEM micrographs of Figure 3, this may be responsible in part for the results observed here. 
The saturation magnetization value for the bare SPIONs of 64 emu/g is lower than the bulk 
value of 92 emu/g as expected in particles of this size and is comparable with results reported 
elsewhere for the size range here of 5 to 20 nm (Mascolo et al., 2013, Kulshrestha et al., 2012). 
Moreover, it was observed that silica and/or lipid coating decreased the saturation 
magnetization of SPIONs further. The lower values due to the silica and lipid coatings are 
given in Table 1 and are expected due to the dilution of the magnetic material content within 
the volume of the sample by the non-magnetic shells. The exact effect of surface coating on 
magnetic properties of SPIONs still remains unclear and different findings have been reported 
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for different kinds of magnetic NPs and coating materials. However, reduction in saturation 
magnetization of Fe3O4 upon coating with silica and lipid has been reported by others 
(Rodrigues et al., 2017, Morales et al., 2019, Husain et al., 2019). Husain et al. and Morales 
and co-workers found that decrease in the saturation magnetization value of SPIONs was 
dependent on the thickness of the silica layer; thicker the silica layer lower is the saturation 
magnetization (Morales et al., 2019, Husain et al., 2019). We have previously observed a 
similar trend for the peptide coated SPIONs and SiSPIONs (Majid et al., 2017).  
 
Table 1: Saturation magnetization and coercivity values for the prepared nanoparticles. 
 
Nanoparticle 
Saturation 
magnetization 
(Ms), emu/g 
Coercivity 
(Hc), kOe 
bSPIONs 64 0.06 
SiSPIONs 41 0.06 
Lip-bSPIONs 13 0.06 
Lip-SiSPIONs 5 0.04 
 
 
TEM results 
 
TEM images show that the prepared nanoparticles are spherical in shape (Figure 3). The 
particles also show aggregation and exhibit polydispersity with size ranging between 5-20 nm 
for bSPIONs (Figure 3 (a)). Further, the bSPIONs were observed to be black in colour 
indicating that the prepared nanoparticles were predominantly magnetite i.e. Fe3O4, however,  
it may also contain a small percentage of brown coloured maghemite i.e. Fe2O3, as reported in 
the literature (Kim et al., 2012, Sharifabad et al., 2015). Both magnetite and maghemite would 
show superparamagnetism at this size and would show similar magnetic properties. The 
powder X-ray diffraction peaks for the synthesized bSPIONs are shown in Figure A1 in the 
Appendix section.  Peaks corresponding to Miller indices 220, 311, 400, 422, 511 and 440 in 
the 2 values between 30 to 70 were observed which are the fingerprint of magnetite Fe3O4 
(Sun et al., 1998). The micrograph for SiSPIONs indicates that the multiple SPION particles 
are coated within a mesoporous silica structure (Figure 3 (b)). SiSPIONs also are polydisperse 
with the average diameter of the particles ~150 nm. The size of the particles further increased 
to ~200 nm upon lipid coating (Figure 3(c)). 
 
Magnetic hyperthermia 
 
The results of magnetic field induced hyperthermia for the prepared nanoparticles as a function 
of time are presented in Figure 4. bSPIONs are the most effective in generating heat in the 
presence of an AC magnetic field and the heat-generating ability decreased for silica and lipid 
coated nanomaterials. In the case of the bSPIONs dispersion, the temperature increased to 
above 43°C within 5 minutes, whereas for the SiSPIONs dispersion, it took twice as much time 
to reach to that temperature. Both types of lipid-coated magnetic nanoparticles showed the 
slowest temperature increase and reached only around 32 °C in 10 minutes of exposure to the 
AC field and took approximately 45 minutes to reach 43 °C (only first 10 minutes shown).  
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Figure 3: TEM images for (a) bSPIONs; (b) SiSPIONs and (c) lipid-SiSPIONs. 
 
SAR values for the dispersion of bSPIONs with a concentration 10 mg/ml was calculated to be 
22.4 W/g. Theoretically, SAR depends on field parameters, strength and frequency as well as 
geometrical and magnetic properties of nanoparticles (Rosensweig, 2002, Kumar and 
Mohammad, 2011). Hence, although a true comparison can only be made using (i) a sample 
vessel of the same size, shape and material, (ii) same size, shape and compostion of core-shell 
SPIONs and (iii) the same dispersion volume concentration; it is interesting to note that similar 
SAR values for bSPIONs have been reported by others (Muller et al., 2005, Zhang et al., 2007, 
Kulshrestha et al., 2012). 
 
The SAR value for the lipid coated SPIONs was found to be 7.7 W/g.  The higher vlaue for the 
bSPIONs compared to the coated particles is not surprising if the heating mechanism is 
hysteresis-dominated as reported elsewhere (Vallejo-Fernandez et al., 2013, Vallejo-Fernandez 
and O'Grady, 2013).  Under AC field conditions, the narrow loops of the near-DC field curves 
of Figure 2 would be open, with distinct remenance and coervivity more typical of that seen in 
the bulk ferrimagnetic material. As the heat generated is proportional to the total area of the 
hysteresis, it is clear that in the coated samples the dilution of magnetic volume fraction by the 
(a)   (b)  
  
     (c)       
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non-magnetic coating will reduce Ms values and hence the hysteresis area. For fully-open loops 
with the same saturation magnetisation of Figure 2 we would expect the heating effect for 
bSPIONs > SiSPIONs > Lip-bSPIONS > Lip-SiSPIONS which is consistent with the measured 
heating effects shown in Figure 4. 
 
 
 
 
Figure 4: Time dependent temperature rise curve for bSPIONs, SiSPION, Lip-bSPION and Lip-SiSPION when 
the particles were subjected to an oscillating magnetic field of frequency 406 kHz and magnetic induction of 200 
gauss. 
 
 
A Similar trend in SAR values has been reported by Kulshrestha et al. for bSPIONs and 
magnetic liposomes with a decrease in the SAR value from 21.5 W/g for SPIONs to 14.2 W/g 
for magnetoliposomes (Kulshrestha et al., 2012). However, Pradhan and co-workers found an 
opposite behaviour and an increase in SAR value of mesoporous silica coated magnetic NPs 
upon lipid coating. They suggested a possible reason could be that the lipid coating provided a 
better dispersion stability to the NPs which enhanced the movement of NPs and thus, 
contributed to the Brownian relaxation and heat generating ability. However, as previously 
mentioned the SAR depends on magnetic field parameters as well as on the properties of NPs, 
concentration etc., so the results cannot be truly compared.     
 
SCM results 
 
Preliminary studies on the dispersion stability of some of the prepared nanoparticles were 
conducted using an SCM. The results from SCM measurements for bSPIONs, extruded 
bSPIONs and Lip-SPIONs are shown in Figure 5. As can be seen from Figure 5(a), bSPIONs 
show poor dispersion stability. The peak in the concentration of particles at the bottom of the 
column shows sedimentation has occurred after only 30 minutes and by 18 hrs a significant 
number of particles are now in the lower layers. As the shift in frequency of the ordinate axis 
is directly proportional to the particle volume concentration and the diameter of the column is 
constant over its height, integration of the profile curves yields a value proportional to the total 
particle content. Hence, 43% of the particles by volume were estimated to have settled out after 
18 hours from the ratio of integration values from the bottom (at 2 cm) over the peak (out to 4 
cm) compared to the value from over the whole of the column. The reduction in F of the  
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Figure 5: SCM profiles of (a) bSPION; (b) Lip-bSPION and (c) bSPION extruded 5 times through 100 nm 
membrane. There is a clear and significant increase in stability due to extrusion of the bSPION colloid, with no 
sedimentation apparent after 18 hours in (c) compared to 43% by volume settled at the bottom of the tube in (a).  
Coating-alone also enhanced stability as shown in (b), where only 13% had settled over the same time period. 
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reasonably flat plateau as a function of time shown in Figure 5(a) is indicative of Stokes’-like 
settling. Here, the particles settle in the same manner as a single particle in an infinite fluid, 
with any distribution in their fall velocities brought about by the distribution of particle 
diameters and with no evidence of the collective phenomena of hindered settling as observed 
in other magnetic suspensions (Mercer and Bissell, 2013).  
 
The Lip-SPIONs are more stable with only 13% estimated to have settled at the bottom after 
18 hours (Figure 5(b)) indicating that the dispersion stability of bSPIONs was significantly 
improved upon coating with lipid. Moreover, the bSPION dispersion which was extruded 5 
times through a 100 nm membrane showed no particle sedimentation after 18 hrs (Figure 5(c)),  
unlike the un-extruded sample in which the particles started settling at the bottom of the SCM  
tube within 30 mins. This is consistent with a significant increase in the number of 
monodisperse nanoparticles in the extruded sample whereas un-extruded bSPIONs showed 
polydispersity, as also seen from TEM (Figure 3 (a)). As colloidal stability is important for 
biological applications (Hufschmid et al., 2019), this result warrants further investigation on 
other SPIONs, both coated and uncoated. Whilst it is generally known that extrusion either 
enhances the stability of NPs and/or aids improved monodispersity (Bartenstein et al., 2016, 
Sabaté et al., 2008), this is not quantified in terms of sedimentation over complete 
concentration profiles. Thus, we show that use of the SCM method provides a simple and 
convenient route to characterise and quantitatively measure this important parameter and to the 
best of our knowledge is reported here in these systems for the first time. 
 
T2 results 
 
The distribution of the T2 relaxation times is reported in Figure 6 and single T2 values for all 
samples are reported in Table 2. Because of the strong dependence of relaxivity from the 
amount of superparamagnetic material, all samples were measured considering the same iron 
oxide concentration at 1.5 mg/mL. At this concentration, bSPIONs showed a single peak of T2 
contribution at 1316 ms and this value is used as a standard for comparison with the other 
samples. Relaxation time analyses for Lip-SPIONs displayed two peaks at 253 ms and 34 ms 
while SiSPIONs showed three peaks at 307 ms, 78 ms and 19 ms. The presence of more than 
one peak can be explained considering the effect of nanoparticles’ aggregation (clustering) and 
the presence of unreacted materials, such as residual lipids or silicon, since the measured 
relaxation times are very close to those of the same reagents in aqueous dispersion. In 
particular, the peaks at higher relaxations times can be attributed to the residual materials while 
peaks at lower relaxation time are related to a different state of aggregation, as confirmed by 
the large relaxation time distribution curves. Indeed, it is well-known that silica has the ability 
to influence the relaxation time distribution due to its hydrophilicity while the lipid contribution 
to relaxivity reduces the relaxation times of the free water molecules (Vecchione et al., 2017a, 
Vecchione et al., 2017b, Russo et al., 2016, De Sarno et al., 2019, Ananta et al., 2010). 
 
However, a significant result in terms of T2 contribution is reported for the Lip-SiSPIONs; 
where a single and low T2 value at 46 ms with a very narrow relaxation time distribution curve 
is shown with respect to the bSPIONs at the same concentration. This result is extremely 
promising since the low T2 value is clinically relevant for the quality of MRI images (Hobson 
et al., 2019) and also because the combination of the lipid and silica for the coating of the 
SPIONs is opening several biological opportunities on the uptake of safer SPIO- based 
nanoparticles. A slight shift is observed for the samples containing doxorubicin even though 
the same trend is also confirmed for all samples. Shortening of T2 relaxation time has been 
reported for SPIONs with surface attached gadolinium complexes and hybrid SPION-
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coordination polymer nanoparticles (Szpak et al., 2014, Borges et al., 2015). The dual-coated 
composite reported here may well provide a new class of SPION-based agents in terms of MRI 
contrast enhancement and further consolidates the suitability of our core-shell SPIONs as 
multi-functional nanoparticles. 
 
 
Figure 6: T2 characteristic relaxation time distributions for the prepared particles. 
 
 
Table 2: T2 values for the prepared nanoparticles 
 
 
 
Drug loading and release results 
 
Both loading and release studies in an incubator were carried out at 37 °C up to 48 hours and 
over the same set of time intervals as shown in Figures 7 (a) and (b) respectively. 
 
The amount of DOX that was entrapped into the nanoparticles at different time intervals was 
determined by using UV spectrophotometer and from the calibration curves for DOX obtained 
using prepared known concentrations (Figure A2). The linear regression fit shown with an R2 
value > 99.85% gives confidence in the conversion of measured absorbance to DOX 
concentration. The entrapment efficiency for Lip-SPIONs after 48 hours was found to be ~35 
% whereas that for Lip-SiSPIONs it was ~58% (Figure 7(a)). The higher loading in SiSPIONs 
could be attributed to the mesoporous structure of silica which reduces drug leakage from the 
nanoparticles and hence shows better entrapment of the drug. There was no significant loading 
between 24-48 hours, whereas maximum drug release was observed after 48 hours (80-90%).  
 
Nanoparticle T2 relaxation peaks (ms) 
 P1 P2 P3 
SPIONs 1316 ±1   
Lip-SPIONs 253 ±5 34 ±6  
SiSPIONs 307 ±1 78 ±1 19 ±2 
Lip-SiSPIONs 46 ±1   
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a) 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
  
 
(c) 
 
 
Figure 7: (a) % entrapment efficiency of DOX in nanocomposites as a function of time; (b): DOX release from 
nanocomposites at 37C as a function of time and (c) comparison of DOX release at 37C in the absence and 
presence of AC magnetic field (n=3; mean ±SD). 
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The release of drug from Lip-SPIONs+DOX and Lip-SiSPIONs+DOX after 48 hours of 
incubation was found to be ~80-85% (Figure 7(b)). For comparison with release at the same 
temperature, but this time achieved using an AC magnetic field as shown in part 2 of Figure 7 
(c), the incubator release at 48 hours is shown again in Part 1 of the same Figure.  In the case 
of the AC field, it took 15 minutes to raise the temperature from RT to 37 °C; at which point 
the sample was removed before carrying out the release measurement. Remarkably, the release 
profiles after this short time are somewhere between those seen at 12 and 24 hours in the 
incubator. As the heating mechanisms of the magnetic AC field method involves physical 
stirring (Brownian rotation), Néel susceptibility and hysteresis losses (Vallejo-Fernandez et al., 
2013) this is very different from the near-static maintaining of a temperature in an incubator 
once it is in equilibrium and warrants further investigation.  
 
For Lip-SPIONs  80% drug release was observed whereas for Lip- SiSPIONs, the drug release 
was seen to be much less, ~ 57%. One possible reason for this may be that the porous silica 
structure results in better entrapment of the drug compared to lipid-coated and thereby hinders 
drug release. Thus, although drug loading is enhanced due to mesoporous silica, the drug 
release is decreased. 
 
In-vitro cytotoxicity results 
The cytotoxicity effect of nanoparticles at 37 °C and after 72 hours is shown in Figure 8 
(particle concentration = 500 µg/ml), against MCF-7 cancer cell lines. Please note, the DOX-
only column is at a concentration of 1 µg/ml as this was the value of the DOX solution used 
for loading the NPs with this drug. Further details are given in the Materials and Methods 
section. The results are shown as percentage cell viability compared to untreated cells.  
 
At this concentration, the cytotoxic effect of nanocomposites for incubation periods of 24 and 
48 hours was less prominent and the cell viability for the dual-coated nanocomposites was 
more than 90%. Hence, the results are only presented for an incubation time of 72 hours. Other 
lower concentrations at 72 hours, of 125 and 250 µg/ml, resulted in values > 73% for the two 
lipid-coated DOX-loaded systems (shown in Figure A3 in the Appendix). As systems above 
70% are considered to be non-toxic (Szuplewska et al., 2019) this prevented a comparison as 
a function of concentration across all the systems studied here. However, it can be noted in 
Figure A3 that there is an overall trend across the samples in terms of lower concentrations 
resulting in higher viability. Whilst this is not conclusive, it can be considered (with caution) 
as indicative in terms of consistency within these results.  
 
From our dose-dependent studies it was observed that bSPIONs induce toxicity at a 
concentration of 250 µg/ml and the cell viability was observed to be <70% (results shown in 
Figure A4 in the Appendix). This value is needed to determine an initial minimum 
concentration level at the start of an investigation.  Similar results were reported previously 
(Sharifabad et al., 2016). At the concentration value then determined and required for the 
coated systems reported here (of 500 µg /ml), the bSPION and SiSPIONs viability are both 
approximately 57% and so are of similar toxicity to the viability value of 53% for DOX-only 
(1 µg/ml), albeit a little less.  
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Figure 8: In vitro cytotoxicity effect of DOX (1 µg/ml), and nanoparticles (with and without DOX) (500 µg/ml 
nanoparticle, which contain 1 µg/ml DOX), in MCF-7 after 72 hours; n=3, mean ±SD, t-test, one-tailed, paired. 
The ends of the horizontal bars above the columns indicate a pair chosen which is statistically significantly 
different. The colours indicate the different levels of significance. Black with values of *p < 0.05, green with **p< 
0.01 and red with ***p<0.001.  
 
For lipid-coated nanoparticles, i.e. Lip-bSPIONs and Lip-SiSPIONs the cell viability was 82% 
and 87% respectively. Hence, as this is greater than 70% it is considered to be biocompatible. 
(Szuplewska et al., 2019). Thus, a clear decrease in toxicity of the nanoparticles was seen for 
Lip-bSPIONs and Lip-SiSPIONs. This yields statistically significant levels of p values, that 
are all < 0.05, when compared to their uncoated counterparts (bSPIONs and SiSPIONs) and is 
indicated by the bars in Figure 8. Moreover, comparison here of our two lipid coated NPs with 
DOX-only, resulted in an even lower value of p <0.001.  
 
Overall, these results indicate that the toxicity of bSPIONs is significantly reduced (p < 0.01) 
upon dual coating the nanoparticles with silica and lipid. 
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For the DOX-loaded lipid-coated NPs, the silica shell of the dual coated bSPIONS resulted in 
a significant increase in cell viability from 55 % to 73% (Lip-bSPIONs+DOX compared to 
Lip-SiSPIONs+DOX) as shown by the bar for the pair in figure 8. This decrease in cytotoxicity 
may be as a result of drug entrapment in the mesoporous structures of the silica coating that 
leads to a slower release of DOX. A similar trend was seen for the toxicity of DOX-loaded NPs 
without lipid coatings (bSPIONs+DOX compared to SiSPIONs+DOX), resulting in an increase 
in cell viability from 36% to 50%. However, in this case the pair are not significantly different.  
 
It is interesting to note that the DOX loaded bSPION is more toxic than DOX or bSPION alone; 
although this should be treated with caution as they cannot be classified as being significantly 
different. It may be possible that physical adsorption between the DOX and bSPION molecules 
is such that the drug is released readily to the cells, but this would require detailed and further 
investigation. 
 
DOX (1 µg/ml), and nanoparticles without DOX, i.e. bSPIONs, SiSPIONs, Lip-SPIONs and 
Lip-SiSPIONs (500µg/ml) were used as controls. IC50 corresponds to the concentration of 
DOX or nanoparticle required to inhibit the growth of cells to 50% compared to the untreated 
cells. IC50 values were determined from the data shown in the dose-dependent cytotoxicity 
curves (Figure A4 in the Appendix) and the results are summarised in Table 3.  The IC50  value 
calculated for DOX-only of 1.1 µg/ml is within the range of 0.68- 1.1 µg/ml (Fang et al., 2014, 
Sharifabad et al., 2016) as previously reported. Upon lipid coating, the IC50 values for bSPIONs 
and SiSPIONs increased which suggests that the lipid layer in both the Lip-bSPIONs and Lip-
SiSPIONs reduces the toxicity and enhances the biocompatibility of the nanoparticles.  
 
Table 3: Calculated IC50 and 95% CI for the control samples after 72 hours. 
 
Test sample 
 IC50 (µg/ml) 
 (95% CI) 
DOX  1.13  (1.06-1.19) 
bSPIONs  610   (566-653) 
SiSPIONs  579   (552-623) 
Lip-bSPIONs  1244   (1114-1374) 
Lip-SiSPIONs  1302   (1166-1438) 
 
In addition, the cell viabilities for all of the nanocomposite systems and at all concentrations 
was tested against non-cancerous SVG p12 cells. In all cases, including exposure for 24, 48 
and 72 hours, the viability was observed to be above 75% (data not shown). Whilst this suggests 
that the NPs are biocompatible and non-toxic towards the non-malignant cells, this should now 
be tested further using non-cancerous breast cells such as MCF-10A. In this case it suggests a 
higher selectivity of NPs to cancer cells compared to healthy cells. Such selectivity of 
magnetoliposomes to cancer cells over the non-malignant cells has been previously reported 
by others (Rodrigues et al., 2017, Szuplewska et al., 2019). The selectivity of nanocomposites 
towards MCF-7 over SVG p12 cells may also be due to differences between morphology, 
permeability and metabolism of normal and cancer cells and increased sensitivity of MCF-7 
cells to DOX.  
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Overall, the results at 37 °C clearly show that the best biocompatibility results are obtained 
from lipid-coatings and the best cytotoxicity is found in systems with silica coatings. Thus, the 
dual-coated lipid-silica magnetic nanocomposite system (Lip-SiSPION) prepared in this work 
offers the best compromise and potentially optimal in-vitro model (MCF-7 and SVGp12) for 
drug delivery and cytotoxicity. This promising result encourages further investigations to be 
carried out under hyperthermic conditions at 42 °C. 
 
Conclusions 
Composite drug carrier systems comprising of core SPIONs coated with silica and/or lipids 
have been developed with promising theranostic properties. To our knowledge, systems 
containing dual coatings of silica and lipid have not been studied for MRI applications as 
contrast agents and are reported here for the first time. In the prepared systems, the ultra-small 
size and superparamagnetic characteristics of SPIONs were retained in the silica and lipid 
coated SPIONs. An initial study on the effects of extrusion on the dispersion stability of bare 
SPIONs resulted in a significant improvement.  Characterisation using an SCM technique 
provided a way of quantifying this important parameter in these bio-compatible magnetic NPs. 
As coated systems are intrinsically more stable than their uncoated SPION cores, such as the 
Lip-SPION system observed here, the extension of this extrusion methodology and SCM 
characterisation to such systems is the subject of further work. The ability to generate heat in 
the presence of an oscillating magnetic field and the favorable drug loading and release profile 
of the Lip-SiSPIONs show the suitability of these nanoparticles for hyperthermia drug delivery 
applications. MRI results indicate a low T2 value and very narrow relaxation time distribution 
curve for Lip-SiSPIONs. As this is clinically important for the quality of the MRI images, these 
dual-coated composites may provide a new class of nanomaterials that enhances their 
effectiveness as contrast agents and warrants further investigation. In addition, lipid-coated 
nanoparticles (without DOX) have shown excellent biocompatibility in-vitro, against breast 
cancer cell line MCF-7 and non-cancerous foetal glial cells, SVG p12. In a preliminary 
investigation, DOX loaded nanocomposites showed high efficiency and selectivity as drug 
carriers against MCF-7 cell lines as compared to SVG p12. However, these results are only 
indicative and further studies are required before any definitive conclusions can be drawn.  
 
The combination of lipid and silica for the dual coating of SPIONs is opening several biological 
opportunities on the uptake of safer SPION-based nanoparticles and hence these 
multifunctional nanoparticles can provide potential theranostic systems for diagnostic and 
targeted drug delivery in hyperthermia-mediated cancer therapy. 
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Appendix 
X-ray Diffraction 
 
Powder X-ray diffraction pattern for bSPIONs is shown in Figure A1. Peaks corresponding to 
Fe3O4 were observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure A1: XRD pattern for bSPIONs 
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DOX calibration curve 
 
A calibration curve was obtained by measuring absorbance of DOX solutions of various 
concentrations at a wavelength of 484nm using a UV spectrophotometer and is presented in 
Figure A2. Serial dilutions of DOX were made in water using 100 µg/ml stock prepared in 1:1 
DMSO:water. From the calibration data points shown, a good linear fit was obtained with an 
R2 value > 99.85%. 
 
 
 
Figure A2: Calibration curve for DOX concentrations, 5, 10, 20, 40, 60 and 80 µg/ml 
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Cellar toxicity at lower concentrations 
 
Cellular toxicity of DOX and the nanoparticles/nanocomposites on MCF-7 after 72 hours at 
lower concentrations of DOX (0.25 and 0.5 µg/ml) and NPs (125 and 250 µg/ml) compared to 
DOX (1 µg/ml ) and NPs (500 µg/ml) of Figure 8 in the Results section are presented in Figure 
A3. 
 
(a) 
 
 
(b) 
 
 
Figure A3: In-vitro cytotoxicity of the nanoparticles and DOX on MCF-7 after 72 hours; n=3, mean ±SD.  
(a) 125 µg/ml of NPs with DOX concentration of 0.25 µg/ml and (b) 250 µg/ml NPs with DOX concentration of 
0.5 µg/ml. Overall there is higher viability across these profiles at lower concentration and so whilst not 
conclusive, is at least indicative of consistency within these results. 
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Dose-dependent cell viability 
 
Dose-dependent cell cytotoxicity of DOX on its own and the control NPs (without DOX), on 
MCF-7 cells is presented in Figure A4.   
    
  (a)        (b) 
       
 
 (c)        (d) 
      
 
(e) 
     
 
Figure A4: Dose-dependent cell cytotoxicity of (a) DOX; (b) bSPIONs; (c) SiSPIONs; (d) Lip-bSPIONs and (e) 
Lip-SiSPIONs on MCF-7 after 72 hours; n=3, mean ±SD. IC50 values were determined from log-linear plots of 
the same as detailed in the Materials and Methods section. 
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